However, the more clinical relevant question is to determine the appropriate treatment window in which CMTs can be administered in order to decrease MMP-9 levels, improve survival, and decrease the sequela of sepsis (i.e. ARDS; liver failure). This evidence concerns the gene MMP9 and Hepatic failure.